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Abstract: Symptom control in patients with moderate to severe persistent asthma is essential 
to reduce the significant morbidity associated with the disease. Poor adherence to controller 
medications has been identified as a major contributing factor to the high level of uncontrolled 
asthma. This review examines patient perspectives on, and preferences for, controller medications 
(inhaled corticosteroid and long-acting β2-agonist combinations [ICS/LABA]), and how this may 
affect adherence to therapy. Fluticasone/salmeterol and budesonide/formoterol, the currently 
available ICS/LABA combination products, have similar efficacy and tolerability based on a 
recent meta-analysis of asthma trials. Adherence is higher with the combination ICS/LABAs 
than when the components are administered separately. Investigations into patient preferences 
for desirable attributes of asthma medications indicate that an effective reliever with a fast 
onset and long duration of action is preferred and may lead to improved adherence. This rapid 
onset of effect was perceived and highly valued in patient surveys, and was associated with 
greater patient satisfaction. Thus, future research should be directed at therapy that offers both 
anti-inflammatory activity and a rapid onset of bronchodilator effect. To further improve patient 
adherence and treatment outcome, the effect of these characteristics as well as other factors on 
adherence should also be investigated.
Keywords: budesonide/formoterol, fluticasone/salmeterol, adherence, onset of effect, patient 
satisfaction
Clinician and patient perspectives  
on asthma control
The overarching goal of asthma management is to achieve and maintain asthma 
control. Moderate to severe persistent asthma is associated with substantial morbidity 
if not adequately controlled.1 Despite the availability of evidence-based strategies for 
maximizing asthma control, the results of a national Web-based survey of 1812 adults 
with persistent asthma indicated that 55% had inadequate control of their asthma 
(Figure 1).2 While this shortcoming may be due in part to the limitations of current 
therapy, the results of the Gaining Optimal Asthma ControL (GOAL) study3 have 
shown that most patients can achieve and maintain guideline-defined control. Using a 
dose escalation strategy, patients with a wide range of asthma severity achieved control; 
at 1 year, 41% of patients had totally controlled asthma with inhaled corticosteroid 
(ICS)/long-acting β2-agonist (LABA) combination therapy versus 28% with ICS alone, 
while 71% maintained at least well-controlled asthma with ICS/LABA versus 59% 
with ICS alone.3 In addition, patients who achieved totally or well-controlled asthma 
for 8 weeks maintained a high level of asthma stability, whereas patients whose asthma Journal of Asthma and Allergy 2009:2 64
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was not well controlled had less stable levels of control and 
were more likely to make unscheduled use of healthcare 
resources.4 As the goal of treatment was to achieve total 
asthma control, most patients were receiving the maximum 
permitted dose of ICS or ICS/LABA by the end of the study. 
Although the study was not designed to establish a clinical 
model for the treatment of asthma, the results indicated that 
optimal control was most likely to occur with ICS/LABA 
combination therapy.
Although it is recognized that asthma control cannot 
be obtained in all patients,3 poor adherence to prescribed 
controller medications is a significant contributor to the 
high level of uncontrolled asthma.5–7 Findings from a 
retrospective analysis of a large healthcare database showed 
that almost half of the patients with asthma failed to renew 
their prescription for controller medication in the first year of 
treatment.8 The results of another retrospective study of 405 
patients with asthma in a Michigan-based health maintenance 
organization revealed that adherence to ICS therapy during 
the 2-year observation period was only 50%, and lack of 
adherence to ICS therapy was responsible for 60% of all 
asthma-related hospitalizations.7
Another reason for suboptimal asthma control may 
be healthcare providers’ failure to implement asthma 
treatment guidelines. Despite concerted efforts over the past 
decade to raise awareness of the NHLBI guidelines among 
primary care physicians, several urban-based studies have 
reported poor provider adherence to key asthma treatment 
recommendations, both in the pediatric-adolescent9,10 and 
adult11,12 outpatient settings. A recent (2003 to 2007) survey 
of 202 adult primary healthcare providers in inner-city 
New York assessed their adherence to 5 NHLBI guideline 
components.12 The survey results revealed suboptimal levels 
of implementation of peak flow monitoring, action plans, and 
referral for allergy testing, as reflected by adherence rates of 
34%, 9%, and 10%, respectively.12 These shortcomings were 
attributed to the physicians’ lack of confidence in their ability 
to effectively implement the guideline recommendations and 
their low expectations of treatment outcome.12
Medication adherence is a complex issue, influenced 
by factors related to patients, healthcare providers, disease 
severity, and therapy. Improving adherence requires an 
approach that addresses these multiple factors.5,13 Findings 
from several studies have shown the need for patient education 
about the importance of daily use of controller medication 
even when symptoms are absent or not bothersome.14–19 
Patients who have a “no symptoms, no asthma” belief have 
been shown to be significantly less likely to use ICS when 
they are asymptomatic and are less likely to engage in other 
self-management behaviors.20
Conversely, certain patient beliefs and perspectives may 
promote adherence to controller medication. For example, 
adherence is higher in those who believe that their controller 
medication is effective.18 Likewise, patients prefer treatments 
with immediate and noticeable effects, since this provides 
assurance that their medication is working.14 The purpose 
of this review is to examine how patient perspectives 
on, and preferences for, controller medication affect 
treatment adherence. The review focuses on the ICS/LABA 
combination products recommended by the NHLBI and 
GINA guidelines for the treatment of moderate to severe 
persistent asthma.21,22
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Figure 1 Healthcare use and missed work/school in the past year in 809 patients with controlled asthma and 1003 patients with uncontrolled asthma. Drawn from data of Peters et al.2
Abbreviation: eD, emergency department.Journal of Asthma and Allergy 2009:2 65
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Combination ICS/LABA  
controller medications
LABA is recommended in combination with ICS for 
long-term control and prevention of symptoms in patients 
aged 5 years or older who have moderate or severe persis-
tent asthma or asthma that is inadequately controlled by 
ICS alone. ICS and LABA can be administered via separate 
inhalers (concurrent therapy) or via a single inhaler contain-
ing both drugs. Two single-inhaler ICS/LABA therapies 
are currently available and have been demonstrated to be 
effective and well tolerated: budesonide in combination 
with formoterol,23–26 and fluticasone in combination with 
salmeterol.27–31 Fluticasone/salmeterol (100/50 µg) is indi-
cated for use in children aged 4 to 11 years, as well as in 
adolescents and adults.32 Currently, budesonide/formoterol 
pressurized metered-dose inhaler (pMDI) is indicated for use 
in individuals aged 12 years or older in the United States.33 
Outside the United States, budesonide/formoterol dry powder 
inhaler (DPI) 80/4.5 µg and 160/4.5 µg doses are approved 
for patients aged 4 years or older, and the 320/9 µg dose is 
indicated for patients aged 12 years or older.
There are several potential advantages to single-inhaler 
combination therapy. Preclinical research has suggested that 
a potential synergy between corticosteroids and β2-agonists 
at the cellular and molecular level may translate into clinical 
benefits if they are deposited in the lungs simultaneously.34 
Furthermore, ICS nonadherence is less likely with the 
combination product in a single inhaler, because it removes 
any confusion or inconvenience associated with the use of 
2 separate inhalers.
Comparative safety and efficacy  
of fixed-dose regimens: budesonide/
formoterol versus fluticasone/salmeterol 
combination therapy
The safety and efficacy of fixed doses of budesonide/
formoterol and fluticasone/salmeterol have been directly 
compared in several large, randomized, controlled trials,35–39 
which formed the basis of a recently published Cochrane 
meta-analysis.40 Drawing on 5 randomized studies including 
data from 5537 adolescent and adult patients with asthma 
(Table 1), the meta-analysis found that budesonide/formoterol 
and fluticasone/salmeterol were equally effective and well 
tolerated, with no significant differences between treatments 
on primary efficacy outcomes (exacerbations requiring oral 
steroids or hospitalization; serious adverse events [including 
asthma-related deaths and intubation]) (Table 2) or secondary 
efficacy outcomes (exacerbations leading to emergency 
department visit/hospital admission, morning and evening 
peak flow, clinical spirometry measures, symptoms, reliever 
medication use, and tolerability).40
Onset of bronchodilator action  
of fixed-dose regimens: budesonide/
formoterol versus fluticasone/ 
salmeterol combination therapy
One characteristic that differs between budesonide/formoterol 
and fluticasone/salmeterol with the potential to influence 
patient preference is the onset of effect. Comparative trials 
have shown that formoterol has a rapid onset of effect, 
similar to that of albuterol, and significantly more rapid than 
that of salmeterol.41,42 Similar results have been found in 
randomized, crossover studies with the combination inhalers 
budesonide/formoterol and fluticasone/salmeterol. When both 
combinations were delivered by DPI, budesonide/formoterol 
(160/4.5 µg and 320/9 µg) showed a significantly faster 
onset of bronchodilatory action than fluticasone/salmeterol 
(250/50 µg), as measured by mean forced expiratory volume 
in 1 second (FEV1) at 3 minutes after inhalation.43,44 Likewise, 
a comparison of the bronchodilatory effects of budesonide/
formoterol pMDI (160/9 µg), fluticasone/salmeterol DPI 
(250/50 µg), and albuterol pMDI (180 µg) showed that the 
improvement in FEV1 observed at 3 minutes after dosing 
was significantly greater with budesonide/formoterol pMDI 
than with fluticasone/salmeterol DPI, and similar to that with 
albuterol pMDI.45
ICS/LABA combination therapy: 
patient adherence, satisfaction,  
and preferences
Adherence to iCS/LABA  
combination therapy
Use of combination ICS/LABA therapy may help with 
patient nonadherence. Administration of the ICS/LABA 
combination in a single inhaler simplifies the treatment 
regimen and improves patient adherence, as shown by 
analyses of medical and pharmacy claims from a large 
managed care organization and Medicaid patients.46,47 
In both analyses, patient adherence was significantly greater 
with fluticasone/salmeterol administered in a single inhaler 
than with the individual drug components administered 
separately. In 1 analysis, short-acting β2-agonist (SABA) 
use was significantly lower when combination fluticasone/
salmeterol therapy was administered in a single inhaler than Journal of Asthma and Allergy 2009:2 66
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when administered separately;47 however, this finding was not 
seen in a study by Stempel and colleagues.46 Retrospective 
analysis of matched cohort data from a Canadian provincial 
healthcare and public drug insurance plan database revealed 
that combination ICS/LABA therapy was associated with 
significantly greater persistence, better treatment adherence, 
fewer asthma exacerbations, and lower use of SABAs than 
concurrent inhaler therapy.8 These studies are retrospective 
and based on pharmacy claims data and not direct measures 
of adherence.
Patient satisfaction with iCS/LABA 
combination therapy
Satisfaction with treatment is an important factor in a patient’s 
resolve to continue daily asthma medication. A search of 
the medical literature on patient preference or satisfaction 
with ICS/LABA therapy was conducted using PubMed, 
EMBASE, and ISI Web of Knowledge (Thomson Reuters), 
as well as a search of clinicaltrials.gov for ongoing trials, 
revealing overall limited information. Patient satisfaction 
with ICS/LABA combination therapy administered from a 
single inhaler was investigated in 2 randomized, double-blind, 
placebo-controlled, 12-week studies of budesonide/formoterol 
pMDI.48,49 In the first study, conducted in 405 patients with 
mild to moderate persistent asthma, budesonide/formoterol 
pMDI 160/9 µg bid was compared with budesonide pMDI 
160 µg bid and formoterol DPI 9 µg bid.49 Patient satisfaction 
was assessed using the Patient Satisfaction with Asthma 
Medication (PSAM) questionnaire,50 a validated, 23-item, 
asthma-specific instrument covering 4 domains: perception of 
medication index, control relief index, comparison with other 
medications index, and inhaler index (this last domain was 
not assessed, because all patients used both types of inhalers 
[pMDI and DPI]). The perception of medication index 
assesses satisfaction with medical benefits received, overall 
perception, influence on sense of well being, and whether a 
patient would recommend the treatment to others. The control 
relief index rates the onset, degree, and duration of symptom 
relief, and the patient’s willingness to continue treatment. 
The comparison with other medications index compares 
the current treatment versus all other inhaled medications 
for onset, degree, and duration of relief. Scores range from 
0 to 100, with 0 representing the lowest level of satisfaction 
and 100 representing the highest.50
After 12 weeks of treatment, mean PSAM scores were 
significantly higher with budesonide/formoterol pMDI than 
with budesonide pMDI or formoterol DPI on all 3 assessed 
indices (Figure 2).49 A greater proportion of patients also 
reported higher satisfaction with budesonide/formoterol pMDI 
than with the other treatments on the individual items within 
each of the 3 assessed PSAM indices. These results suggest not 
only that treatment with budesonide/formoterol pMDI leads to 
greater satisfaction with asthma medication, but also that both 
components contribute to this improvement.49
In the second study, patient-reported outcomes were 
compared in 553 adults with moderate to severe persistent 
Table 2 Primary outcomes of a meta-analysis comparing the efficacy and safety of fluticasone/salmeterol versus budesonide/formoterol 
combination therapy40
Outcome Study Fluticasone/  
salmeterol n/N (%)
Budesonide/
formoterol n/N (%)
Odds ratio (95% CI)
exacerbations requiring 
oral steroid treatment
Busse et al37 37/404 (9.2) 37/422 (9.2) 1.05 (0.65, 1.69)
Kuna et al39 109/1199 (9.1) 108/1099 (9.8) 0.92 (0.69, 1.21)
Dahl et al38 63/694 (9.1) 79/697 (11.3) 0.78 (0.55, 1.11)
Total 209/2297 (9.1) 224/2218 (10.1) 0.89 (0.73, 1.09)
exacerbations requiring 
hospitalization
Aalbers et al36 0/219 (0.0) 1/215 (0.5) 0.33 (0.01, 8.04)
Busse et al37 2/404 (0.5) 1/422 (0.2) 2.09 (0.19, 23.19)
Kuna et al39 15/1123 (1.2) 13/1105 (1.2) 1.14 (0.54, 2.40)
Dahl et al38 4/694 (0.6) 1/697 (0.1) 4.03 (0.45, 36.19)
Total 21/2440 (0.8) 16/2439 (0.7) 1.29 (0.68, 2.47)
Asthma-related serious 
Aes
Aalbers et al36 0/224 (0.0) 1/215 (0.5) 0.32 (0.01, 7.86)
Kuna et al39 15/1119 (1.3) 12/1099 (1.1) 1.23 (0.57, 2.64)
Dahl et al38 6/697 (0.9) 1/700 (0.1) 6.07 (0.73, 50.55)
Total 21/2040 (1.0) 14/2014 (0.7) 1.47 (0.75, 2.86)
Notes: Odds ratio represents the event risk for fluticasone/salmeterol relative to budesonide/formoterol.
Abbreviations: AEs, adverse events; CI, confidence interval.Journal of Asthma and Allergy 2009:2 68
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asthma who were randomized to treatment with budesonide/
formoterol pMDI 320/9 µg bid (administered via a single 
inhaler), budesonide pMDI 320 µg bid plus formoterol DPI 
9 µg bid (administered consecutively via 2 separate inhalers), 
budesonide pMDI 320 µg bid, formoterol DPI 9 µg bid, or 
placebo.48 Patient health-related quality of life was assessed 
using the standardized Asthma Quality of Life Questionnaire 
(AQLQ[S]),51 the Medical Outcomes Survey (MOS) Sleep 
Scale,52 and the PSAM questionnaire. No significant 
differences in patient-related outcomes were noted between 
budesonide/formoterol and budesonide plus formoterol 
(ie, between combination therapy administered from a single 
inhaler versus 2 separate inhalers); however, end-of-treatment 
improvements in AQLQ(S) overall and domain scores and in 
PSAM scores for control relief and perception of medication 
were significantly greater with budesonide/formoterol pMDI 
than with the individual components.
Patient preferences for attributes  
of asthma therapy
Conjoint analysis is a technique used in market research to 
investigate the relative importance of groups of attributes of 
consumer products, and it can also be used to analyze patient 
preferences for various treatment options.53 It provides a 
method for comparing the value to the patient of desirable 
attributes (eg, efficacy) versus undesirable ones (eg, high 
cost) and for identifying which factors influence patient 
preference for one regimen over another. Patient preference 
for attributes of asthma medication was investigated using 
conjoint analysis in a Swedish study involving 298 adult 
patients with asthma receiving ICS plus SABA, ICS 
plus LABA, or ICS/LABA.54 Different combinations of 
6 attributes of asthma treatment were rated by questionnaire 
with predefined levels for each attribute. These included: 
(1) type of maintenance treatment (ICS alone, LABA + ICS, 
or ICS/LABA in a single inhaler); (2) need for additional 
inhaler for acute symptom relief (yes/no); (3) time to onset of 
action of reliever (3 minutes, 10 to 15 minutes); (4) duration 
of action of reliever (3 to 6 hours, 12 hours); (5) number of 
symptom-free days per month (10, 10 to 14, 15 to 20, 20); 
and (6) out-of-pocket costs per month (Sk100, 240, 380, 520). 
Conjoint analysis showed that patients focused primarily 
on the effectiveness of treatment. While the most important 
aspect of asthma maintenance treatment was the number of 
symptom-free days, this was found only when the number of 
symptom-free days increased from 10 to 20 per month. 
The highest-ranked preferences were treatment with a reliever 
with fast onset and long duration of action (preferred by 78% 
of patients) and treatment with an ICS/LABA combination 
inhaler rather than separate inhalers (preferred by 50% of 
patients). The preferred asthma regimen was an ICS/LABA 
combination that could be used for both controller and reliever 
therapy. Overall, 85% of patients preferred an alternative 
treatment to their current regimen and were willing to pay 
more (on average about US$36) for the alternative.54
More recently, a US nationwide telephone survey of 
200 randomly selected adults with asthma was conducted 
to establish the factors that influence patients’ adherence 
to asthma controller medication.55 When questioned about 
treatment-related factors that might improve their adherence, 
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Figure 2 Mean Patient Satisfaction with Asthma Medication (PSAM) index scores at the end of 12 weeks of treatment with budesonide/formoterol, budesonide alone, formoterol 
alone, or placebo. Drawn from data of Murphy et al.49
Abbreviations: DPi, dry powder inhaler; pMDi, pressurized metered-dose inhaler.Journal of Asthma and Allergy 2009:2 69
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the most frequent responses were: (1) “If it controlled my 
symptoms better”; (2) “If it had long-lasting control of my 
symptoms”; (3) “If it meant I would need rescue medication 
less often”; (4) “If it meant I would need less additional medi-
cation to control my asthma overall”; (5) “If I knew I would 
feel better and could be more active without having asthma 
symptoms”; and (6) “If I could feel it helping my asthma 
soon after taking it.” Nonadherence was primarily the 
consequence of an active decision to use medication only as 
needed. A subgroup of patients who reported poor adherence 
to their controller medication (n = 75) listed different factors 
that might improve their adherence: (1) “If I could do more 
things I normally can’t do now”; (2) “If I could feel it helping 
my asthma soon after taking it”; (3) “If it had long-lasting 
control of my symptoms”; (4) “If it controlled my symptoms 
better”; (5) If it meant I would need rescue medication less 
often”; and (6) “If I could be certain that it was safe.” Many 
of the 200 patients strongly preferred a medication that 
worked quickly; this preference was especially apparent in 
the nonadherent group.55
Patient preference for a rapid bronchodilator effect has 
been investigated recently using a newly developed measure, 
the Onset of Effect Questionnaire (OEQ).56 The OEQ is a 
validated weekly diary that elicits ratings for 5 items: during 
the past week (1) you could tell that your study medication 
was working; (2) you could feel your study medication begin 
to work right away; (3) you felt physical sensations shortly 
after taking your medication that reassured you that it was 
working; (4) your study medication worked as quickly as your 
albuterol; and (5) you were satisfied with how quickly you 
felt your study medication begin to work.56 Perception of, and 
satisfaction with, the feeling that controller therapy is working 
right away as measured by the OEQ items 2 and 5 has been 
shown to be a significant predictor of overall satisfaction with 
medication and satisfaction with the onset and duration of relief 
of asthma symptoms, as assessed by the PSAM (Figure 3).56 
This suggests that patients who perceive that their medication 
is acting rapidly will not only receive positive reinforcement 
from use of the medication, but will also be more satisfied with 
treatment, possibly resulting in better treatment adherence.56 
In 2 double-blind, randomized, placebo-controlled clinical 
trials employing the OEQ in asthma, significantly more 
budesonide/formoterol-treated patients than budesonide- or 
placebo-treated patients reported that they could feel their 
study medication beginning to work right away.57
Clinicians’ perspectives regarding the value to the patient 
of a perceived rapid onset of treatment effect have also been 
evaluated.58 A 12-member consensus panel of community-based 
healthcare professionals who reviewed the above-mentioned 
OEQ findings with budesonide/formoterol pMDI, but were 
blinded to the drug name,56 unanimously concluded that the fact 
that patients could feel their medication working right away was 
clinically relevant and meaningful to decision making, and that 
this attribute might improve patient adherence.58
Patient satisfaction with iCS/LABA: 
budesonide/formoterol versus 
fluticasone/salmeterol
Patient satisfaction with the budesonide/formoterol pMDI 
(adjustable-dose and fixed-dose) compared with the fluticasone/
salmeterol DPI has been assessed using the Asthma Treatment 
n = 115
n = 130 n = 130 n = 131 n = 131
n = 115 n = 114 n = 114
P < 0.001 Yes No
Patients who answered “yes” or “no”
on the OEQ item: “I could feel the
medication begin to work right away.” 
Patients who answered “yes” or “no”
on the OEQ item: “I was satisfied with how
quickly I felt the medication begin to work.”
PSAM index:     Overall perception of
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Figure 3 relationship between perception of, and satisfaction with, the feeling that medication is working right away on the Onset of effect Questionnaire (OeQ) and ratings 
from the Patient Satisfaction with Asthma Medication (PSAM) index on satisfaction with medication and asthma symptom relief scores. Drawn from data of Murphy et al.49Journal of Asthma and Allergy 2009:2 70
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Satisfaction Measure (ATSM)59 in a large, randomized, 
open-label, multicenter, 7-month study of adult patients with 
moderate to severe persistent asthma.60 The ATSM is a newly 
developed, validated instrument that incorporates the domains 
of patient expectations, treatment preferences, self-reported 
treatment outcomes, and overall treatment satisfaction.59 As 
measured by the ATSM, patient satisfaction with treatment 
was greater with budesonide/formoterol (adjustable dose 
or fixed dose) than with fixed-dose fluticasone/salmeterol. 
Patients receiving adjustable-dose budesonide/formoterol 
reported significantly greater satisfaction on the ATSM 
overall score and scores for feel medication working, 
dosing management, and timely relief of symptoms compared 
with those receiving fixed-dose fluticasone/salmeterol. 
Patients receiving fixed-dose budesonide/formoterol reported 
significantly greater satisfaction for timely relief of symptoms 
and feel medication working scores than those receiving fixed-
dose fluticasone/salmeterol.60
In summary, assessment of patient satisfaction and 
preference for treatment provides insight into those features 
of combination controller medication that are important to 
patients and may lead to greater treatment adherence. These 
assessments showed that the rapid onset of bronchodilator 
effect associated with budesonide/formoterol was highly 
valued by patients and was associated with greater patient 
satisfaction than was fluticasone/salmeterol. However, it is 
important to note that patients’ stated preference for rapid 
onset of effect does not necessarily mean improved adherence 
to therapy will be a direct result. Further studies are needed 
to evaluate the impact of this characteristic of an ICS/LABA 
combination on adherence.
Implications for future clinical 
research and development
Use of combination therapy for both 
controller and reliever therapy
Research suggests that patients would prefer an ICS/LABA 
combination that could be used as both controller and reliever 
medication.54 The strategy of using a single ICS/LABA 
for both controller and reliever therapy, known by the 
acronym SMART (Symbicort® [budesonide/formoterol] 
Maintenance and Reliever Therapy), is currently approved 
outside the United States. Symbicort SMART is based on 
the premise that for patients who are already receiving a 
daily maintenance dose of budesonide/formoterol, use of 
as-needed budesonide/formoterol would allow more rapid 
adjustment of anti-inflammatory therapy in conjunction with 
rapid relief of symptoms. More rapid ICS adjustment, in turn, 
is associated with improved asthma control. At the same 
time, the LABA component would provide rapid symptom 
relief. This premise has been confirmed by findings from 
numerous studies;39,61–65 however, further research is needed 
to determine if it leads to improved adherence to therapy.
The rapid onset of effect of formoterol is advantageous 
not only because it allows the combination with budesonide 
to be used as both controller and reliever therapy, but also 
because it contributes to patient satisfaction with treatment.56 
Pharmaceutical research and development should be 
directed toward combination therapies with rapid-acting 
LABAs, because of the importance to patients of rapid 
onset of action.54,56 Promising new ICS/rapid-acting LABA 
combinations include ciclesonide/formoterol, mometasone/
formoterol, fluticasone/formoterol, and mometasone/
indacaterol. Investigation into patient preference and the 
impact on adherence with these medications will be essential 
as we continue to advance asthma care.
Conclusions
Advances in the management of asthma are aimed at providing 
therapies that are not only safe and effective, but also have the 
potential for overcoming insufficient medication adherence, 
which is a critical barrier to successful treatment. Treatment 
with ICS/LABA is highly effective and recommended for 
patients whose asthma is not controlled on ICS alone. Combi-
nation treatment with a single inhaler is preferred by patients 
and is associated with improved adherence compared with 
ICS alone or ICS and LABA in separate inhalers.
In addition to the convenience of a single inhaler, patients 
prefer medications with a rapid onset of effect. Patients who 
exhibit poor adherence believed that a rapid onset of effect 
would improve their adherence to treatment. Currently available 
data based on patients’ perspectives on ICS/LABA therapy 
suggests that patients receiving rapidly acting combination 
therapy perceive immediate benefit from their medication 
and experience high levels of satisfaction with treatment. 
Research is needed to evaluate if patient preference for a drug 
with rapid onset of effect results in improved adherence to 
therapy and outcome. Thus, future research should be directed 
at combination therapy that offers not only anti-inflammatory 
activity, but a rapid onset of bronchodilator effect.
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